Juvenile idiopathic arthritis

Researchers Provide a Better Understanding of sJIA and Still’s Disease
Sourced from publicdomainpictures.net (https://www.publicdomainpictures.net/en/view-image.php?image=275669&picture=chemical-research)

Researchers Provide a Better Understanding of sJIA and Still’s Disease

According to Healio, medical professionals from Boston Children's Hospital have conducted research that provides a better look at systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease. They looked specifically…

Continue Reading Researchers Provide a Better Understanding of sJIA and Still’s Disease
Simponi Aria (Golimumab) Approved for Juvenile Arthritis Types pJIA and jPsA
https://pixabay.com/en/baby-child-cute-doll-expression-17366/

Simponi Aria (Golimumab) Approved for Juvenile Arthritis Types pJIA and jPsA

Recently, the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen") announced the FDA approval of Simponi Aria (golimumab). The therapy is designed to treat pediatric patients (ages 2 or older)…

Continue Reading Simponi Aria (Golimumab) Approved for Juvenile Arthritis Types pJIA and jPsA
Juvenile Arthritis Awareness Month: Teen Living with Juvenile Idiopathic Arthritis Isn’t Slowing Down
source: pixabay.com

Juvenile Arthritis Awareness Month: Teen Living with Juvenile Idiopathic Arthritis Isn’t Slowing Down

According to a story from gopresstimes.com, Lily Laurent, a 13 year old student at De Pere middle school in Wisconsin, has lived with juvenile idiopathic arthritis for nine years. While…

Continue Reading Juvenile Arthritis Awareness Month: Teen Living with Juvenile Idiopathic Arthritis Isn’t Slowing Down
Ankylosing Spondylitis Treatment Approved but Not Yet Available
https://pixabay.com/en/approved-pass-ok-approval-symbol-1726357/

Ankylosing Spondylitis Treatment Approved but Not Yet Available

According to Ankylosing Spondylitis News, a new treatment, Hulio, has been approved by the FDA. It is a treatment for ankylosing spondylitis and other inflammatory disorders. Although it has been…

Continue Reading Ankylosing Spondylitis Treatment Approved but Not Yet Available
The First Treatment for Adult-Onset Still’s Disease Just Got FDA Approved
source: pixabay.com

The First Treatment for Adult-Onset Still’s Disease Just Got FDA Approved

According to a story from PR Newswire, the US Food and Drug Administration (FDA) has just approved a treatment for rare adult-onset Still's disease for the first time ever. The…

Continue Reading The First Treatment for Adult-Onset Still’s Disease Just Got FDA Approved
Early Treatment of Juvenile Idiopathic Arthritis Improves Outcomes, Inactivates Disorder
IAOM-US / Pixabay

Early Treatment of Juvenile Idiopathic Arthritis Improves Outcomes, Inactivates Disorder

According to Juvenile Arthritis News, treating juvenile idiopathic arthritis early helps reduce symptoms, nearly "inactivating" the condition. The Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) JIA Registry found that early…

Continue Reading Early Treatment of Juvenile Idiopathic Arthritis Improves Outcomes, Inactivates Disorder
New Task Force Recommends Shared Decision-Making for Parents and Patients with Juvenile Idiopathic Arthritis
source: pixabay.com

New Task Force Recommends Shared Decision-Making for Parents and Patients with Juvenile Idiopathic Arthritis

  According to a recent article in BioMed Central, an international task force formed in 2018 created guidelines for the treatment of juvenile idiopathic arthritis (JIA). Treatment targets were identified…

Continue Reading New Task Force Recommends Shared Decision-Making for Parents and Patients with Juvenile Idiopathic Arthritis
Study: Felty’s Syndrome Presents Differently in Pediatric Patients
source: pixabay.com

Study: Felty’s Syndrome Presents Differently in Pediatric Patients

According to a study published in BMC Pediatrics, the rare disease known as Felty's syndrome is primarily known to affects adults between the ages of 50 and 70, but on very rare…

Continue Reading Study: Felty’s Syndrome Presents Differently in Pediatric Patients
ICYMI: Johnson & Johnson and the UK Government: Genomics For Disease Prevention
source: pixabay.com

ICYMI: Johnson & Johnson and the UK Government: Genomics For Disease Prevention

  Janssen R&D, a division of Johnson & Johnson (J&J), has partnered with the UK Biobank and others according to a recent news release by 3BL Media. It is noteworthy…

Continue Reading ICYMI: Johnson & Johnson and the UK Government: Genomics For Disease Prevention
Searching for the Cause of Lung Disease in Systemic Juvenile Idiopathic Arthritis
source: pixabay.com

Searching for the Cause of Lung Disease in Systemic Juvenile Idiopathic Arthritis

  According to a recent article in MedPage Today’s 2019 year-end review, the number of life-threatening lung diseases in systemic juvenile idiopathic arthritis (sJIA) patients has been increasing. sJIA is…

Continue Reading Searching for the Cause of Lung Disease in Systemic Juvenile Idiopathic Arthritis
The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease
source: pixabay.com

The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease

According to a story from Business Wire, the biopharmaceutical company Bristol-Myers Squibb has recently announced that the US Food and Drug Administration (FDA) has granted the company's drug abatacept (marketed…

Continue Reading The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease
The Drug Tofacitinib Appears Effective for Juvenile Idiopathic Arthritis in Clinical Trial
source: pixabay.com

The Drug Tofacitinib Appears Effective for Juvenile Idiopathic Arthritis in Clinical Trial

According to a story from Juvenile Arthritis News, the results of a recent phase 3 clinical trial indicate that the drug tofacitinib (marketed as Xeljanz) can be an effective treatment…

Continue Reading The Drug Tofacitinib Appears Effective for Juvenile Idiopathic Arthritis in Clinical Trial
Doctors Call for Screening of Juvenile Idiopathic Arthritis Patients to Identify Rare Lung Disease
nastya_gepp / Pixabay

Doctors Call for Screening of Juvenile Idiopathic Arthritis Patients to Identify Rare Lung Disease

According to a story from newswise.com, biologic medicines have had a major positive impact on outcomes for patients with the rare disease juvenile idiopathic arthritis (JIA). However, as these medicines…

Continue Reading Doctors Call for Screening of Juvenile Idiopathic Arthritis Patients to Identify Rare Lung Disease
Potential Link Between a Treatment for Systemic Juvenile Idiopathic Arthritis and Lung Disease

Potential Link Between a Treatment for Systemic Juvenile Idiopathic Arthritis and Lung Disease

The number of systemic juvenile idiopathic arthritis patients who develop lung disease (sJIA-LD) is rising in both the U.S., Europe, the Middle East, and Canada. This trend has been notable…

Continue Reading Potential Link Between a Treatment for Systemic Juvenile Idiopathic Arthritis and Lung Disease
Early Use of Infliximab Offers Benefits for Juvenile Idiopathic Arthritis Patients
Pexels / Pixabay

Early Use of Infliximab Offers Benefits for Juvenile Idiopathic Arthritis Patients

According to a story from Juvenile Arthritis News, a recent study from China has found that early treatment with infliximab (marketed as Remicade) can reduce inflammation and indicators of active…

Continue Reading Early Use of Infliximab Offers Benefits for Juvenile Idiopathic Arthritis Patients
Study Finds The Drug Arava May be Useful for Juvenile Idiopathic Arthritis
JillWellington / Pixabay

Study Finds The Drug Arava May be Useful for Juvenile Idiopathic Arthritis

According to a story from Juvenile Arthritis News, a recent study has found that the drug leflunomide (marketed as Arava) may be a viable treatment for juvenile idiopathic arthritis patients,…

Continue Reading Study Finds The Drug Arava May be Useful for Juvenile Idiopathic Arthritis
Study Shows The Shared Decision-Making Model Improves Outcomes for JIA Patients

Study Shows The Shared Decision-Making Model Improves Outcomes for JIA Patients

Juvenile idiopathic arthritis (JIA) is a rare condition affecting children. Like all patients, these children are told what treatment they need and then they are expected to comply. However, researchers in…

Continue Reading Study Shows The Shared Decision-Making Model Improves Outcomes for JIA Patients
Biosimilar Drug for Ankylosing Spondylitis gets Approved by the FDA
stevepb / Pixabay

Biosimilar Drug for Ankylosing Spondylitis gets Approved by the FDA

According to a story from Ankylosing Spondylitis News, the drug Hadlima, which is a biosimilar to the drug Humira (adalimumab), was recently approved by the US Food and Drug Administration…

Continue Reading Biosimilar Drug for Ankylosing Spondylitis gets Approved by the FDA
Study Determines More Research is Needed Regarding the Effect of Body Weight on Juvenile Idiopathic Arthritis

Study Determines More Research is Needed Regarding the Effect of Body Weight on Juvenile Idiopathic Arthritis

The Study Juvenile idiopathic arthritis (JIA) is a rare disease that causes inflammation in the joints. It is of unknown origin and has no cure. Previous investigations in studies with…

Continue Reading Study Determines More Research is Needed Regarding the Effect of Body Weight on Juvenile Idiopathic Arthritis
We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.
Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Partner With Us
Submit a Story
Become a Contributor

Keep Up to Date

Subscribe to Our Newsletter
Check Out Rare Events
Get Inspired By Our Memes

Learn More

About Us
Rare Diseases and Conditions
Terms of Use
Privacy Policy

© Copyright Patient Worthy

Close Menu